Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
Best Penny Stocks To Buy: 4 Short Squeeze Stocks To Watch Now
01:29pm, Monday, 08'th Aug 2022
Penny stocks to buy: Here's what short interest traders think The post Best Penny Stocks To Buy: 4 Short Squeeze Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information
Why Karyopharm Therapeutics Inched Higher Today
10:13pm, Thursday, 04'th Aug 2022 The Motley Fool
The company's second-quarter performance had some highlights, but investors might have been concerned about full-year guidance.
Why Karyopharm Therapeutics Inched Higher Today
06:13pm, Thursday, 04'th Aug 2022
The company's second-quarter performance had some highlights, but investors might have been concerned about full-year guidance.
Karyopharm Therapeutics (KPTI) Q2 2022 Earnings Call Transcript
05:30pm, Thursday, 04'th Aug 2022 The Motley Fool
KPTI earnings call for the period ending June 30, 2022.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
01:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 1.59% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q2 2022 Results - Earnings Call Transcript
11:49am, Thursday, 04'th Aug 2022
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Che
Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022
07:09am, Thursday, 28'th Jul 2022
-- Conference Call Scheduled for Thursday, August 4, 2022, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
04:58pm, Wednesday, 15'th Jun 2022
Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
05:08pm, Thursday, 26'th May 2022
– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxiciti
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
07:00am, Tuesday, 10'th May 2022
NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compan
Karyopharm Therapeutics (KPTI) Q1 2022 Earnings Call Transcript
03:30am, Friday, 06'th May 2022 The Motley Fool
KPTI earnings call for the period ending March 31, 2022.
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q1 2022 Results - Earnings Call Transcript
09:38pm, Thursday, 05'th May 2022
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng
Analyst Ratings for Karyopharm Therapeutics
09:03pm, Thursday, 05'th May 2022 Benzinga
Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
01:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
